New Scalp Treatment Shows Promise for Hair Loss
There’s an experimental scalp treatment called clascoterone that seems to be making waves in the battle against male pattern baldness, or androgenetic alopecia (AGA). Experts are expressing optimism about its potential, suggesting it might offer a fresh way to tackle hair loss that hasn’t been seen in decades.
Two significant late-stage trials, known as Scalp 1 and Scalp 2, were conducted by Ireland’s Cosmo Pharmaceuticals. In total, 1,465 men from the United States and Europe participated in these studies.
Possible Breakthrough for Hair Restoration
Participants were given either the topical solution or a placebo in a randomized setup. The main measure of success was the “target area hair count” (TAHC) — basically, the number of hairs in a specific spot on the scalp.
Cosmo Pharmaceuticals stated that the solution works by blocking dihydrotestosterone (DHT), the hormone responsible for shrinking genetically sensitive hair follicles, right at the receptor sites rather than altering the hormone itself throughout the body.
This topical method aims to get at the heart of the biological causes of AGA without introducing additional hormones into the system.
In the Scalp 1 trial, clascoterone demonstrated a remarkable 539% improvement in hair count compared to the placebo group, while Scalp 2 participants had a relative improvement of 168%. This data was highlighted in their press release.
“There aren’t really any creams or lotions that are very effective for hair removal, so this may be worthy of widespread clinical use.”
One of the studies noted “statistical significance” in patient-reported outcomes, and the other indicated a favorable trend. When the data from both trials were analyzed together, the improvements were described as “statistically significant” and corresponded to the hair count findings.
Dr. Maria Hordinsky, a dermatology professor at the University of Minnesota, emphasized that patients have often faced limited treatment options of questionable efficacy and safety due to systemic exposure to hormones, leading to some patients not addressing their hair loss at all.
“These findings show that a 5% topical solution of clascoterone could change that landscape by delivering real, measurable regrowth with minimal systemic exposure,” Hordinsky remarked.
Additionally, the overall responses from patients regarding their perceived hair growth were positive.
Expert Opinions on Clascoterone
Dr. Mark Siegel, a senior medical analyst, expressed optimism too, stating, “This looks promising. There have really been no effective creams or lotions for hair loss.” He highlighted that minoxidil lotion, a widely utilized FDA-approved treatment, has limited effectiveness, making this new approach potentially valuable for various clinical applications.
Considering Limitations and Risks
Dr. Siegel pointed out that the drug appears fundamentally safe, with the only noted side effect being “local inflammation.” The side effects reported were minimal and occurred at similar rates in both the treatment and placebo groups, with most being unrelated to the drug.
However, the improvement found in participants compared to the placebo doesn’t guarantee that all men will see a fivefold increase in hair growth relative to other treatments.
Individual results may differ based on how much hair one had to begin with. And it’s important to note that complete data on visible growth isn’t available yet.
Siegel did caution that, as an anti-androgen, the cream could cause allergic reactions and, in rare instances, adrenal insufficiency. That’s because the treatment blocks male hormones, which might slightly impact the adrenal glands responsible for managing stress hormones.
Complete data on long-term effects and changes in hair count is still pending, and researchers have yet to publish information on the prolonged safety of the treatment over 12 months.
If this product gains approval, it would represent a significant advance, being the first treatment designed specifically for male hair loss that acts by blocking DHT directly in hair follicles.
Cosmo Pharmaceuticals is aiming to finalize a complete safety follow-up by spring 2026 before seeking regulatory approval in both the U.S. and Europe.
